Kyowa Kirin Co (KYKOF) Stock Research

Over a week ago

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial

May 12, 9:48 AM

Citi gets more bearish on Kyowa Kirin, downgrades shares

KYKOF

Mar 9, 5:33 AM

Morgan Stanley gets more bearish on Kyowa Kirin, downgrades shares

KYKOF

Mar 6, 4:47 AM

SMBC Nikko gets more bearish on Kyowa Kirin, downgrades shares

KYKOF

Mar 4, 9:06 AM

Kyowa Kirin just downgraded at JPMorgan, here's why

KYKOF

Mar 3, 12:53 PM

Kyowa Kirin announces discontinuation of rocatinlimab clinical trials

Mar 3, 8:20 AM

Kyowa Kirin to regain control of rocatinlimab development, commercialization

Jan 30, 8:16 AM

Kyowa Kirin just downgraded at Goldman Sachs, here's why

KYKOF

Dec 16, 8:32 AM

Kura Oncology receives $30M development milestone payment for ziftomenib

Oct 24, 7:04 AM

Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial

Oct 1, 7:12 AM

No more stories

Proprietary Biologics Technology Platforms: Kyowa Kirin possesses unique and advanced technology platforms, such as POTELLIGENT and COMPLEGENT, for developing highly effective and differentiated antibody-based drugs, enabling them to create best-in-class or first-in-class therapies.

Focused Therapeutic Area Leadership: The company strategically concentrates its R&D and commercial efforts on specific, high-value therapeutic areas like oncology, nephrology, and immunology, allowing them to build deep expertise, establish strong market positions, and address critical unmet medical needs.

Robust and Innovative R&D Pipeline: Kyowa Kirin maintains a strong pipeline of novel drug candidates across various development stages, driven by significant investment in research and a commitment to discovering and developing breakthrough medicines with global potential.

Clinical Development and Regulatory Approval Risks: Failure to successfully complete clinical trials or obtain timely regulatory approvals for new products could significantly impact future revenue and growth.

Intense Competition and Market Erosion Risks: Kyowa Kirin faces strong competition from other pharmaceutical companies, including generic and biosimilar manufacturers, which could erode market share and profitability of its existing and pipeline products.

Patent Expiry and Intellectual Property Risks: The expiry of patents for key products or the inability to effectively protect its intellectual property could lead to a decline in sales due to increased competition from generic or biosimilar versions.